Tremelimumab is a fully human monoclonal antibody specific for human cytotoxic T lymphocyte-associated antigen 4. Administration of tremelimumab to patients with locally advanced and metastatic melanoma has resulted in a subset of patients with durable objective tumour regressions. Our echocardiographic images impressively show the effects of this new antibody in a patient with cardiac metastatic malignant melanoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975197 | PMC |
| http://dx.doi.org/10.1159/000360127 | DOI Listing |
Publication Analysis
Top Keywords
remission intracardiac
4
intracardiac melanoma
4
melanoma metastasis
4
metastasis tremelimumab
4
tremelimumab therapy
4
therapy tremelimumab
4
tremelimumab fully
4
fully human
4
human monoclonal
4
monoclonal antibody
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!